Fluzoparib
- Generic Name
- Fluzoparib
- Drug Type
- Small Molecule
- Chemical Formula
- C22H16F4N6O2
- CAS Number
- 1358715-18-0
- Unique Ingredient Identifier
- TWF0ML1CK8
- Background
Fluzoparib is under investigation in clinical trial NCT03863860 (A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients).
- Indication
⑴适用于既往经过二线及以上化疗的伴有胚系BRCA突变(gBRCAm)的铂敏感复发性卵巢癌、输卵管癌或原发性腹膜癌患者的治疗。⑵适用于铂敏感的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者在含铂化疗达到完全缓解或部分缓解后的维持治疗。
A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Tianjin Medical University Second Hospital
- Target Recruit Count
- 53
- Registration Number
- NCT04659785
- Locations
- 🇨🇳
Tianjin Medical University Second Hospital, Tianjin, Tianjin, China
Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
- First Posted Date
- 2020-09-02
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Target Recruit Count
- 1
- Registration Number
- NCT04535687
- Locations
- 🇨🇳
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
Bioequivalence of Fluzoparib(SHR3162) Study on Healthy Chinese Adult Subjects
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04521192
- Locations
- 🇨🇳
The affiliated hospital of QingDao university, Qingdao, Qingdao, China
A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients
- Conditions
- Relapsed Ovarian Cancer
- Interventions
- Drug: Fluzoparib+Apatinib
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT04517357
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 74
- Registration Number
- NCT04425876
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT04400188
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer
- Conditions
- Breast CancerMetastatic Cancer
- Interventions
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 319
- Registration Number
- NCT04355858
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2020-04-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT04341077
A Trial of SHR3162 in Healthy Caucasian Volunteers
- First Posted Date
- 2020-04-03
- Last Posted Date
- 2022-07-14
- Lead Sponsor
- Atridia Pty Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT04333134
- Locations
- 🇦🇺
Atridia Pty Limited, Sydney, New South Wales, Australia
A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 5
- Registration Number
- NCT04300114
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
🇨🇳The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳Chinese PLA General Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.